Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

(SEOUL, Republic of Korea — September 14th at 10:45 a.m. Korea Standard Time) —An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

The study was also published today in the Journal of Thoracic Oncology, the official journal of IASLC.

In patients with stage II-IIIA disease, the eight-year overall survival rate was 74% with osimertinib compared with 58% with placebo, a 16-percentage-point difference. The hazard ratio for overall survival was 0.53 (95% CI, 0.38-0.75).

Across the overall stage IB-IIIA population, the eight-year overall survival rate was 79% with osimertinib versus 64% with placebo, a 15-percentage-point difference. The overall survival hazard ratio was 0.52 (95% CI, 0.39-0.71), and benefit was observed across predefined subgroups.

ADAURA is a global Phase III, double-blind, randomized trial that enrolled 682 patients with completely resected EGFR-mutated stage IB-IIIA NSCLC. Patients were randomized to receive once-daily osimertinib 80 mg or placebo for up to three years; adjuvant chemotherapy was permitted. All patients had already had the opportunity to complete three years of study treatment before this long-term exploratory analysis. The updated analysis extends earlier ADAURA findings demonstrating statistically significant disease-free survival and overall survival benefits with adjuvant osimertinib. Three years of adjuvant osimertinib is the standard of care in this setting.

“These additional long-term findings further characterize the established survival benefit of adjuvant osimertinib for patients with resected EGFR-mutated stage IB-IIIA NSCLC, with or without adjuvant chemotherapy,” said Roy Herbst, M.D., Phd, of Dartmouth Cancer Center, Lebanon, N.H.  This is the first study to establish the new paradigm that bringing the best targeted drugs to patients with earlier-stage disease can delay progression and improve survival. We have come such a long way in the 30 years since EGFR inhibitors were first introduced into clinical practice, and this is great news for our patients.

###

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.